| Active Not Recruiting | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With NCT04092270 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors NCT03641287 | University of Washington | N/A |
| Active Not Recruiting | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R NCT02839707 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Re NCT02502266 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared NCT02446600 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713 | Mayo Clinic | Phase 2 |
| Completed | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube NCT02283658 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, NCT02101775 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Can NCT02068794 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavi NCT02111941 | Mayo Clinic | EARLY_Phase 1 |
| Completed | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent O NCT01489371 | Gynecologic Oncology Group | Phase 1 |
| Unknown | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previo NCT00719303 | Gynecologic Oncology Group | Phase 3 |
| Completed | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian NCT01504126 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients Wi NCT01459380 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherap NCT01275664 | Gynecologic Oncology Group | N/A |
| Completed | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, NCT00888615 | GOG Foundation | Phase 2 |
| Active Not Recruiting | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage NCT01167712 | National Cancer Institute (NCI) | Phase 3 |
| Completed | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritone NCT01080521 | Gynecologic Oncology Group | — |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851 | National Cancer Institute (NCI) | Phase 3 |
| Unknown | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745 | GOG Foundation | Phase 3 |